

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED

JAN 02 2001

File Information Unit

In re Application of

Bendig

Application Number

08/186269

Filed

11/21/98

Group Art Unit

Examiner

Paper No. #19

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

(A) referred to in United States Patent Number 5840299, column _____,

(B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____,

(C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

(D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Nancy Perry

Signature

Nancy Perry

Typed or printed name

1/2/01

Date

FOR PTO USE ONLY

Approved by: GP

File Information Unit

Unit:



US005840299A

United States Patent [19]**Bendig et al.**[11] **Patent Number:** **5,840,299**[45] **Date of Patent:** **Nov. 24, 1998**[54] **HUMANIZED ANTIBODIES AGAINST
LEUKOCYTE ADHESION MOLECULE
VLA-4**[75] Inventors: **Mary M. Bendig**, London; **Olivier J. Léger**, Hertfordshire; **José Saldanha**, Enfield Middlesex; **S. Tarran Jones**, Radlett, all of United Kingdom; **Ted A. Yednock**, Fairfax, Calif.[73] Assignee: **Athena Neurosciences, Inc.**, South San Francisco, Calif.[21] Appl. No.: **561,521**[22] Filed: **Nov. 21, 1995****Related U.S. Application Data**

[63] Continuation-in-part of Ser. No. 186,269, which is a continuation-in-part of PCT/US95/01219 Jan. 25, 1995, abandoned.

[51] Int. Cl.⁶ **A61K 39/395**; C07K 16/28;
C12P 21/08; C12N 15/13[52] U.S. Cl. **424/133.1**; 424/130.1;
424/141.1; 424/143.1; 424/144.1; 424/153.1;
424/154.1; 424/173.1; 435/7.1; 435/7.2;
435/7.21; 435/7.24; 435/69.6; 435/172.3;
435/251.3; 435/320.1; 530/387.3; 530/388.73;
530/388.75; 530/388.22; 536/23.53[58] Field of Search 424/130.1, 133.1,
424/141.1, 143.1, 144.1, 153.1, 154.1, 173.1;
435/69.6, 172.3, 252.3, 320.1, 7.1, 7.2,
7.21, 7.24; 536/23.4, 23.5, 23.53; 530/387.1,
387.3, 388.2, 388.22, 388.7, 388.73, 388.75[56] **References Cited****U.S. PATENT DOCUMENTS**5,260,210 11/1993 Rubin et al. 435/240.23
5,530,101 6/1996 Queen et al. 530/387.3**FOREIGN PATENT DOCUMENTS**239400 9/1987 European Pat. Off. C12N 15/00
330506 8/1989 European Pat. Off. C07K 15/06
XWO 90/07861 7/1990 WIPO C12P 21/00
XWO 91/03252 3/1991 WIPO A61K 37/10
91/05038 4/1991 WIPO C12N 5/06
XWO 93/15764 8/1993 WIPO A61K 39/395**OTHER PUBLICATIONS**X Lisak et al. J. Neurol. Sciences 62: 281-293 (1983).
X Teitelbaum et al. PNAS 89: 137-141 (1992).
X Weiner et al. Science 259: 1321-1324 (1993).
X Racke et al. J. Neuroimmunol. 46: 175-184 (1993).
X Karussis et al. PNAS 90: 6400-6404 (1993).

X Cannella et al. Ann Neurol. 37: 424-435 (1995).

X Washington et al. Ann Neurol 35: 89-97 (1994).

X Dore-Duffy et al. in Frontiers in Cerebral Vascular Biology: Transport and its Regulation (eds) Dreues and Betz Plenum Press Ny 1993 pp. 243-248.

X Monshizadegan et al., "VLA-4-dependent adhesion activities of U937 cells and guinea pig bronchoalveolar lavage leukocytes", 1993. *Agents Actions* 39, pp. C177-C179.X Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation", 1991. *Protein Engineering*, vol. 4, No. 7, pp. 773-783.Yednock et al. "Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha 4 \beta 1$ integrin", 1991. *Letters to Nature*, vol. 356, pp. 63-66.W. J. Harris and S. Emery. "Therapeutic antibodies—the coming of age", 1993. *Tibtech*, vol. 11, pp. 42-45.S. C. Emery and J. R. Adair. "Humanised monoclonal antibodies for therapeutic applications", 1994. *Exp. Opin. Invest. Drugs*, vol. 3, pp. 241-251.S. M. Edgington. "How Sweet It Is: Selectin-Mediating Drugs", 1992. *Bio/Technology*, vol. 10, pp. 383-389.Elices et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site", 1990. *Cell*, vol. 60, pp. 577-584.Dijkstra et al., "Multiple sclerosis: some possible therapeutic opportunities", 1993. *Tips Reviews*, vol. 14, pp. 124-129.A. Mountain and J.R. Adair, "Engineering Antibodies for Therapy", 1992. *Biotech Genetic Engineering Reviews*, vol. 10, pp. 10-13.P.A. Ward and M.S. Mulligan. "Blocking of adhesion molecules in vivo as anti-inflammatory therapy", 1994. *Therapeutic Immunol*, vol. 10, pp. 165-171.L. K. Jolliffe. "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering", 1993. *Intern Rev Immunol*, vol. 10, pp. 241-250.

X Albelda Faseb J. 8: 504-512 (1994).

X Kahan Curr Opin Immunology 4: 553-560 (1992).

X Natanson et al. Ann Intern Med. 120: 771-783 (1994).

X Dalakas Ann. Neurol. 37(51): 52-513 (1995).

X Paul (ed) Fundamental Immunology Raven Press NY 1993 p. 242 only.

X **Primary Examiner**—Lila Feisee**Assistant Examiner**—Phillip Gambel**Attorney, Agent, or Firm**—Townsend & Townsend & Crew LLP

[57]

ABSTRACT

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.

29 Claims, 16 Drawing Sheets